Janssen Biotech to buy BeneVir Biopharm in $1bn deal

01:47 EDT 3 May 2018 | Pharmaceutical Business Review

Janssen Biotech has agreed to acquire US-based BeneVir Biopharm, a biopharmaceutical company focused on developing oncolytic immunotherapies for cancer, in a deal worth $1.04bn.

Original Article: Janssen Biotech to buy BeneVir Biopharm in $1bn deal


More From BioPortfolio on "Janssen Biotech to buy BeneVir Biopharm in $1bn deal"

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...